The Department of Health and Human Services’ mRNA pullback only applies to their use in upper respiratory disease, according ...

Papzimeos is the first immunotherapy approved for recurrent respiratory papillomatosis, a rare lung disorder involving the ...

The move comes after Robert F. Kennedy Jr. received pressure from the Children’s Health Defense, an anti-vaccine non-profit ...

As Trump has pressured drugmakers to lower the cost of medicines in the U.S., the pharma industry has coalesced behind a ...

The Boston-based AI/ML startup focuses on endocrine and cardiometabolic diseases and will use that expertise to generate new ...

The death was linked to acute kidney injury in a patient who had a single kidney remaining and a “complex medical history,” ...

WARN notices provide a heads up that staff will soon be unemployed, but the act that mandates them has some nuances. An ...

The HHS secretary recently canceled $500 million worth of BARDA contracts around mRNA vaccine research. But the U.S.

Citing other priorities—such as the upcoming U.S.-Russia summit—four anonymous sources claim that pharma tariffs could still ...

After two patients who received the investigational CDC7 blocker died, pushing forward with SGR-2921’s development would be ...

Vedanta is parting ways with 23 employees, or approximately 20% of its headcount, after Phase II data for microbiome therapy ...

In this episode of Denatured, BioSpace’s head of insights Lori Ellis discusses the ‘enormous implications’ of patent policy ...